Clinical and Genetic Risk Factors for Acute Incident Venous Thromboembolism in Ambulatory Patients With COVID-19

Article Public, Environmental & Occupational Health

Trends in Disease Severity and Health Care Utilization During the Early Omicron Variant Period Compared with Previous SARS-CoV-2 High Transmission Periods — United States, December 2020–January 2022

A. Danielle Iuliano et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2022)

Article Infectious Diseases

Venous or arterial thrombosis and deaths among COVID-19 cases: a European network cohort study

Edward Burn et al.

Summary: The incidence of venous thromboembolism and arterial thromboembolism among COVID-19 cases is up to 1% and increases with hospitalization. These events are associated with excess mortality.

LANCET INFECTIOUS DISEASES (2022)

Add to Collection

Article Medicine, General & Internal

Risks of deep vein thrombosis, pulmonary embolism, and bleeding after covid-19: nationwide self-controlled cases series and matched cohort study

Ioannis Katsoularis et al.

Summary: A study in Sweden found that COVID-19 is a risk factor for deep vein thrombosis, pulmonary embolism, and bleeding. The study used self-controlled case series and matched cohort studies to investigate 1,057,174 individuals who tested positive for SARS-CoV-2 in Sweden.

BMJ-BRITISH MEDICAL JOURNAL (2022)

Add to Collection

Review Cardiac & Cardiovascular Systems

Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials

Luis Ortega-Paz et al.

Summary: This study presents evidence from randomized controlled trials comparing different prophylactic anticoagulation regimens among hospitalized patients with COVID-19. The findings suggest that standard-dose prophylactic anticoagulation is more suitable than escalated-dose regimen, as it does not reduce all-cause death but increases the risk of major bleeding.

EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY (2022)

Add to Collection

Article Medicine, General & Internal

Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19 The ACTIV-4B Randomized Clinical Trial

Jean M. Connors et al.

Summary: This study aimed to assess the impact of anticoagulant or antiplatelet therapy on symptomatic clinically stable outpatients with COVID-19. The results showed that treatment with aspirin or apixaban compared with placebo did not reduce the rate of a composite clinical outcome, and the study was terminated early due to a lower than anticipated event rate.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Article Respiratory System

Arterial and venous thromboembolism in COVID-19: a study-level meta-analysis

Boun Kim Tan et al.

Summary: The prevalence of VTE is high in COVID-19 patients, especially in those admitted to the ICU, while the prevalence of ATE is relatively low and further research is needed.

THORAX (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization and death in outpatients with COVID-19: The PREVENT-HD study

Warren H. Capell et al.

Summary: The PREVENT-HD trial aims to evaluate the efficacy and safety of rivaroxaban as a prophylactic anticoagulation treatment in outpatient settings for COVID-19 patients, to reduce the risks of thrombotic events, hospitalization, and mortality associated with COVID-19.

AMERICAN HEART JOURNAL (2021)

Add to Collection

Article Education, Scientific Disciplines

COVID-19 and thrombosis: searching for evidence

Bright Thilagar et al.

Summary: This article presents a case-based review of thromboembolic prophylaxis in COVID-19 and briefly discusses the epidemiology, pathophysiology, and rare occurrence of vaccine-induced thrombotic thrombocytopenia.

HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2021)

Add to Collection

Article Medicine, General & Internal

Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19 The HEP-COVID Randomized Clinical Trial

Alex C. Spyropoulos et al.

Summary: Therapeutic-dose low-molecular-weight heparin reduces major thromboembolism and death in high-risk inpatients with COVID-19, with no significant effect observed in critically ill patients.

JAMA INTERNAL MEDICINE (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19

Azita H. Talasaz et al.

Summary: COVID-19 induces endothelial injury and thrombosis, but the optimal thromboprophylactic regimens are still unknown across the spectrum of illness severity. Ongoing randomized controlled trials are assessing various antithrombotic agents, doses, and durations, presenting opportunities and challenges for the clinical trial enterprise.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)

Add to Collection

Editorial Material Medicine, General & Internal

SARS-CoV-2 Vaccine-Induced Immune Thrombotic Thrombocytopenia

Douglas B. Cines et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

News Item Medicine, General & Internal

Covid-19: US suspends Johnson and Johnson vaccine rollout over blood clots

Elisabeth Mahase

BMJ-BRITISH MEDICAL JOURNAL (2021)

Add to Collection

Review Hematology

Prevalence and risk factors of thrombotic events on patients with COVID-19: a systematic review and meta-analysis

Xiaoming Xiong et al.

Summary: This study revealed a high prevalence of thrombosis in COVID-19 patients, especially in the ICU, indicating the importance of closely monitoring D-dimer, LDH, WBC, and lymphocyte levels.

THROMBOSIS JOURNAL (2021)

Add to Collection

Article Hematology

Extensive Thromboembolism in a Young Male with Asymptomatic COVID-19 Infection and Heterozygous Factor V Leiden Mutation

Florian Appenzeller et al.

Summary: This case report discusses a 21-year-old male who, previously healthy, developed extensive thromboembolism in the context of asymptomatic COVID-19 infection and heterozygous factor V Leiden mutation.

HAMOSTASEOLOGIE (2021)

Add to Collection

Article Medicine, General & Internal

Thromboembolic Risk in Hospitalized and Nonhospitalized COVID-19 Patients: A Self-Controlled Case Series Analysis of a Nationwide Cohort

Frederick K. Ho et al.

Summary: Confirmed COVID-19 infection was associated with early elevations in risk of MI and ischemic stroke, and substantially stronger and prolonged elevations in risk of DVT and PE, both in hospital and community settings. Thromboembolism, especially PE, should be considered among people with COVID-19 in the community.

MAYO CLINIC PROCEEDINGS (2021)

Add to Collection

Article Medicine, General & Internal

Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19

Ewan C. Goligher et al.

Summary: In critically ill patients with Covid-19, initial therapeutic-dose anticoagulation did not result in improved survival rates or fewer days requiring cardiovascular or respiratory organ support compared to usual-care pharmacologic thromboprophylaxis.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Pharmacology & Pharmacy

Venous thromboembolism in COVID-19 compared to non-COVID-19 cohorts: A systematic review with meta-analysis

Vicky Mai et al.

Summary: A systematic review and meta-analysis compared the rate of venous thromboembolism (VTE) between COVID-19 and non-COVID-19 cohorts, finding no significant difference overall, but indicating an increased risk of VTE in COVID-19 patients hospitalized in the intensive care unit (ICU).

VASCULAR PHARMACOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study

Julia Hippisley-Cox et al.

Summary: The study found increased risks of haematological and vascular events leading to hospital admission or death within short time intervals after first doses of the ChAdOx1 nCoV-19 and BNT162b2 mRNA vaccines. The risks of these events were higher and more prolonged after SARS-CoV-2 infection compared to vaccination in the same population.

BMJ-BRITISH MEDICAL JOURNAL (2021)

Add to Collection

Editorial Material Medicine, General & Internal